MINNEAPOLIS--(BUSINESS WIRE)--April 19, 2006--MGI PHARMA, INC. (NASDAQ:MOGN - News), an oncology- and acute care-focused biopharmaceutical company, today reported total revenue for first quarter 2006 of $78.2 million. GAAP net loss for the first quarter 2006 was $2.8 million, or $0.04 per diluted share. Pro forma net loss for the first quarter of 2006 was $1.0 million, or $0.01 per diluted share, as is described below under “Reconciliation of GAAP to Pro Forma Net Income (Loss).” At March 31, 2006, MGI PHARMA’s cash and marketable debt investments totaled $109.5 million.
